0001261380-15-000033.txt : 20150618
0001261380-15-000033.hdr.sgml : 20150618
20150618184647
ACCESSION NUMBER: 0001261380-15-000033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150617
FILED AS OF DATE: 20150618
DATE AS OF CHANGE: 20150618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRIDEX CORP
CENTRAL INDEX KEY: 0001006045
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770210467
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1230
BUSINESS ADDRESS:
STREET 1: 1212 TERRA BELLA AVE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 6509404700
MAIL ADDRESS:
STREET 1: 1212 TERRA BELLA AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Steckel Ronald
CENTRAL INDEX KEY: 0001304121
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27598
FILM NUMBER: 15941095
MAIL ADDRESS:
STREET 1: C/O FOXHOLLOW TECHNOLOGIES, INC.
STREET 2: 740 BAY ROAD
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-06-17
0001006045
IRIDEX CORP
IRIX
0001304121
Steckel Ronald
1212 TERRA BELLA AVENUE
MOUNTAIN VIEW
CA
94043
0
1
0
0
VP, Operations
Common Stock
2015-06-17
4
M
0
625
3.856
A
30625
D
Common Stock
2015-06-17
4
S
0
625
8.7674
D
30000
D
Common Stock
2015-06-17
4
M
0
1041
3.99
A
31041
D
Common Stock
2015-06-17
4
S
0
1041
8.7674
D
30000
D
Stock Option Right to Buy
3.856
2015-06-17
4
M
0
625
0
D
2013-02-01
2017-01-01
Common Stock
625
11875
D
Stock Option Right to Buy
3.99
2015-06-17
4
M
0
1041
0
D
2003-04-16
2016-04-16
Common Stock
1041
10417
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Selling Plan adopted by the reporting person on 12/5/14.
The sales price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold, ranging from $8.75 to $8.84 per share. Upon request by the Commission staff, the Issuer, or a security holder of Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
This option was granted pursuant to IRIDEX Corporation's 2008 Equity Incentive Plan and is exempt to Rule 16b-3.
The shares are subject to vesting according to the following schedule: 1/48th of the total number of shares vest each month.
The shares shall vest as follows: 12/48ths of the shares shall vest 12 months after the Vesting Commencement Date and 1/48th of the shares shall vest each month thereafter.
/s/ Susan Bruce, Attorney-iin-Fact
2015-06-18